Genitourinary Cancers | Specialty

Impact of the Phase 3 CheckMate 9ER Trial on Practice

December 14th 2020

The Role of VEGF TKI Monotherapy

December 14th 2020

Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

December 14th 2020

Risk Assessment and Diagnostic Work-up

December 14th 2020

Improved Outcomes With Novel and Combination Therapies

December 14th 2020

Tumor Biology in Favorable to Poor-Risk RCC

December 14th 2020

The Biology of RCC and Improved Treatment Outcomes

December 14th 2020

ctDNA Positivity Correlates With Improved Survival With Atezolizumab in High-Risk Muscle-Invasive Bladder Cancer

December 12th 2020

Circulating tumor DNA positivity identified patients with high-risk muscle-invasive urothelial cancer who were likely to derive improvements in disease-free survival and overall survival from adjuvant atezolizumab vs observation.

Positive EU Opinion Granted to Avelumab for Frontline Maintenance in Locally Advanced or Metastatic Urothelial Carcinoma

December 11th 2020

December 11, 2020 - The European Medicine Agency’ s Committee for Medicinal Products for Human Use has granted a positive opinion to avelumab as a single agent, frontline maintenance option for adult patients with locally advanced or metastatic urothelial carcinoma who are free of disease progression after platinum-based chemotherapy.

Renal Cell Carcinoma and Novel Therapies

December 11th 2020

As the biology of renal cell carcinoma becomes better understood, so does the management of the disease, including the use of novel therapies.

Nadofaragene Firadenovec Continues to Show Strong Activity in BCG-Unresponsive High-Grade NMIBC

December 2nd 2020

December 2, 2020 - Patients with high-grade Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer who responded to the investigational gene therapy nadofaragene firadenovec had a lower rate of cystectomy and delayed time to cystectomy compared with those who did not respond.

New Strategies Enhance Care in mUC

November 25th 2020

November 25, 2020 — Although metastatic urothelial carcinoma remains generally incurable, management of bladder cancer has witnessed several multidisciplinary advances in the past few years.

FDA Approves Durvalumab for Fixed-Dose Use in NSCLC, Bladder Cancer Indications

November 20th 2020

November 20, 2020 - The FDA has approved durvalumab for an additional dosing option, a fixed dose of 1500 mg every 4 weeks, in the approved indications of unresectable stage III non-small cell lung cancer after chemoradiation and previously treated advanced bladder cancer.

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

November 18th 2020

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

UGN-102 Elicits Durable Responses in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

November 17th 2020

November 17, 2020 - Primary chemoablation with UGN-102 was found to induce durable responses in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Novel Mechanism of Action and Tolerability Makes Telaglenastat a Promising Player in RCC

November 17th 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

Cabozantinib Plus Nivolumab/Ipilimumab Under Exploration in Intermediate-, Poor-Risk RCC

November 14th 2020

November 14, 2020 - A novel combination comprised of the TKI cabozantinib plus the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab is under exploration in treatment-naïve patients with intermediate or poor risk advanced or metastatic renal cell carcinoma in the phase 3 COSMIC-313 trial.

Dr. George on the Specificity of Cabozantinib in RCC

November 13th 2020

Daniel J. George, MD, discusses the expanding role of cabozantinib in renal cell carcinoma.

Dr. Lee on the Rationale for Evaluating Telaglenastat in RCC

November 13th 2020

Chung-Han Lee, MD, PhD, discusses the rationale for evaluating telaglenastat in renal cell carcinoma.

Dr. Campbell on the Expanding Role of Cabozantinib in RCC

November 12th 2020

Matthew T. Campbell, MD, MS, discusses the expanding role of cabozantinib in renal cell carcinoma.